{
    "ticker": "ZVSA",
    "name": "Zevra, Inc.",
    "description": "Zevra, Inc. is an innovative biotechnology company focused on developing novel therapies for chronic diseases, particularly in the field of rare and orphan diseases. Founded in 2020, Zevra aims to address unmet medical needs by leveraging advanced scientific research and cutting-edge technology. The company is dedicated to bringing forward unique treatments that target the underlying causes of diseases rather than just managing symptoms. With a robust pipeline of drug candidates, Zevra is actively engaged in clinical trials to evaluate the safety and efficacy of its therapies. The team comprises experienced professionals from the pharmaceutical and biotech industries, committed to transforming the lives of patients through their groundbreaking work. Zevra's mission revolves around improving patient outcomes and enhancing quality of life by providing effective and accessible treatment options. In addition to its research and development efforts, Zevra places a significant emphasis on collaboration with academic institutions and industry partners to foster innovation and expedite the drug development process. The company's commitment to transparency and ethical practices ensures that it meets the highest standards of regulatory compliance and patient safety throughout its operations.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2020",
    "website": "https://www.zevra.com",
    "ceo": "Jane Doe",
    "social_media": {
        "twitter": "https://twitter.com/ZevraBio",
        "linkedin": "https://www.linkedin.com/company/zevra-inc/"
    },
    "investor_relations": "https://ir.zevra.com",
    "key_executives": [
        {
            "name": "Jane Doe",
            "position": "CEO"
        },
        {
            "name": "John Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ZV-101",
                "ZV-202"
            ]
        }
    ],
    "seo": {
        "meta_title": "Zevra, Inc. | Innovative Biotechnology Solutions",
        "meta_description": "Explore Zevra, Inc., a biotechnology company dedicated to developing therapies for chronic and rare diseases. Learn about our innovative pipeline and commitment to patient care.",
        "keywords": [
            "Zevra",
            "Biotechnology",
            "Rare Diseases",
            "Therapeutics",
            "Chronic Disease Treatment"
        ]
    },
    "faq": [
        {
            "question": "What is Zevra known for?",
            "answer": "Zevra is known for developing novel therapies for chronic and rare diseases."
        },
        {
            "question": "Who is the CEO of Zevra?",
            "answer": "Jane Doe is the CEO of Zevra, Inc."
        },
        {
            "question": "Where is Zevra headquartered?",
            "answer": "Zevra is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Zevra's main products?",
            "answer": "Zevra's main products include ZV-101 and ZV-202."
        },
        {
            "question": "When was Zevra founded?",
            "answer": "Zevra was founded in 2020."
        }
    ],
    "competitors": [
        "AMGN",
        "GILD",
        "REGN"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRNA",
        "BMY"
    ]
}